Arvinas, Inc. ARVN
We take great care to ensure that the data presented and summarized in this overview for ARVINAS, INC. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding ARVN
View all-
Vanguard Group Inc Valley Forge, PA8.56MShares$90.5 Million0.0% of portfolio
-
Black Rock Inc. New York, NY6.26MShares$66.2 Million0.0% of portfolio
-
Logos Global Management LP San Francisco, CA5.58MShares$58.9 Million5.5% of portfolio
-
D. E. Shaw & Co., Inc. New York, NY3.35MShares$35.4 Million0.02% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny2.13MShares$22.5 Million0.01% of portfolio
-
State Street Corp Boston, MA1.87MShares$19.8 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA1.67MShares$17.7 Million0.0% of portfolio
-
Morgan Stanley New York, NY1.66MShares$17.6 Million0.0% of portfolio
-
Tcg Crossover Management, LLC Palo Alto, CA1.62MShares$17.1 Million1.54% of portfolio
-
New Leaf Venture Partners, L.L.C. New York, NY1.59MShares$16.8 Million31.25% of portfolio
Latest Institutional Activity in ARVN
Top Purchases
Top Sells
About ARVN
Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer (mCRPC); ARV-471, a PROTAC protein degrader targeting the estrogen receptor protein for the treatment of patients with metastatic ER positive/HER2 negative breast cancer; and ARV-766 an investigational orally bioavailable PROTAC protein degrader for the treatment of men with mCRPC. The company has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., and Bayer AG. Arvinas, Inc. was founded in 2013 and is based in New Haven, Connecticut.
Insider Transactions at ARVN
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Nov 07
2025
|
David K Loomis Chief Accounting Officer |
SELL
Open market or private sale
|
Direct |
230
-0.72%
|
$2,070
$9.89 P/Share
|
|
Sep 22
2025
|
Briggs Morrison Director |
BUY
Open market or private purchase
|
Direct |
30,000
+28.3%
|
$210,000
$7.57 P/Share
|
|
Jun 25
2025
|
Sunil Agarwal Director |
BUY
Grant, award, or other acquisition
|
Direct |
16,025
+34.69%
|
-
|
|
Jun 25
2025
|
Alsup Laurie Smaldone Director |
BUY
Grant, award, or other acquisition
|
Direct |
16,025
+38.09%
|
-
|
|
Jun 25
2025
|
Edward Moore Kennedy Jr. Director |
BUY
Grant, award, or other acquisition
|
Direct |
16,025
+28.9%
|
-
|
|
Jun 25
2025
|
Linda Bain Director |
BUY
Grant, award, or other acquisition
|
Direct |
16,025
+38.09%
|
-
|
|
Jun 25
2025
|
John D Young Director |
BUY
Grant, award, or other acquisition
|
Direct |
16,025
+38.09%
|
-
|
|
Jun 25
2025
|
Briggs Morrison Director |
BUY
Grant, award, or other acquisition
|
Direct |
16,025
+25.83%
|
-
|
|
Jun 25
2025
|
Leslie V Norwalk Director |
BUY
Grant, award, or other acquisition
|
Direct |
16,025
+38.09%
|
-
|
|
Jun 25
2025
|
Everett Cunningham Director |
BUY
Grant, award, or other acquisition
|
Direct |
16,025
+38.09%
|
-
|
|
Jun 24
2025
|
Andrew Saik Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
5,700
-3.35%
|
$39,900
$7.61 P/Share
|
|
Jun 17
2025
|
Angela M Cacace Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
2,583
-1.65%
|
$18,081
$7.49 P/Share
|
|
May 09
2025
|
Noah Berkowitz Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
59,600
+26.0%
|
-
|
|
May 09
2025
|
Angela M Cacace Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
59,600
+27.54%
|
-
|
|
May 09
2025
|
Andrew Saik Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
59,600
+25.95%
|
-
|
|
May 09
2025
|
David K Loomis Chief Accounting Officer |
BUY
Grant, award, or other acquisition
|
Direct |
11,825
+27.82%
|
-
|
|
Mar 18
2025
|
Noah Berkowitz Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
8,658
-7.3%
|
$69,264
$8.59 P/Share
|
|
Feb 24
2025
|
Angela M Cacace Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
4,207
-2.09%
|
$67,312
$16.65 P/Share
|
|
Feb 24
2025
|
David K Loomis Chief Accounting Officer |
SELL
Open market or private sale
|
Direct |
1,214
-6.05%
|
$19,424
$16.75 P/Share
|
|
Feb 24
2025
|
John G Houston President and CEO |
SELL
Open market or private sale
|
Direct |
31,338
-1.32%
|
$501,408
$16.65 P/Share
|
Last 12 Months Summary
| Grant, award, or other acquisition | 655K shares |
|---|---|
| Open market or private purchase | 30K shares |
| Open market or private sale | 63K shares |
|---|